methylnitrosourea has been researched along with telapristone acetate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christov, K; Lantvit, D; Wiehle, R; Yamada, T | 1 |
| Choi, MR; Christov, K; Ivancic, D; Khan, SA; Lee, O | 1 |
2 other study(ies) available for methylnitrosourea and telapristone acetate
| Article | Year |
|---|---|
CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.
Topics: Animals; Apoptosis; Carcinogens; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mammary Neoplasms, Animal; Methylnitrosourea; Models, Biological; Norpregnadienes; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Progesterone | 2011 |
Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Hormone Antagonists; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Methylnitrosourea; Mice; Mifepristone; Neovascularization, Pathologic; Norpregnadienes; Progesterone; Progestins; Rats; Receptors, Estrogen; Receptors, Progesterone; Time Factors | 2016 |